Skip to main content
. Author manuscript; available in PMC: 2012 Jul 1.
Published in final edited form as: Neuropharmacology. 2011 Mar 21;61(1-2):112–120. doi: 10.1016/j.neuropharm.2011.03.014

Table 1.

RTI-113 IC50 values for selected transporter mutants. One-way ANOVA was performed followed by Dunnett’s post-hoc analysis to see if the mNET mutants were significantly different from the wild type mNET.

Transporter RTI-113 IC50 [nM] uptake inhibition Dunnett’s post-hoc versus mNET (n=3–6), p value
mNET 170±25.3
mNET-TM8m 269±35.8 <0.05
mNET-TM6m 341±77.2 <0.05
mNET-TM3m 1.89±1.29 <0.001

mDAT 0.65±0.28 <0.001
mDAT F155Y 13.4±1.9 <0.001 (versus mDAT)

mNET Y151F 12.1±0.8 <0.001
mNET Y151A 130±15.1 n/s
mNET Y151C 211±23.0 n/s
mNET Y151D 306±105 n/s
mNET Y151E 770±55.3 0.001
mNET Y151G 165±28.4 n/s
mNET Y151H Low uptake
mNET Y151I 199±65.1 n/s
mNET Y151K 453±71.0 <0.01
mNET Y151L 342±110 n/s
mNET Y151M 679±174 <0.01
mNET Y151N 291±51.5 n/s
mNET Y151P Low uptake
mNET Y151Q 831±69.0 <0.01
mNET Y151R Low uptake
mNET Y151S 99.3±43.8 n/s
mNET Y151T 115±33.2 n/s
mNET Y151V 181±81.1 n/s
mNET Y151W 256±66.9 n/s